The pandemic modellers have a conflict of interest problem
John Edmunds is on top of the world. He’s one of the modelling-paper mafiosi. The London, U.K., professor is a key government advisor on COVID-19-related policies.
Edmunds also was a co-author of one of the primary modelling papers that have been used to convince the masses that vigilance against Variant of Concern (VOC) B.1.1.7 should be their top priority.
And Edmunds co-wrote an influential January 21, 2021 report that concluded:
There is a realistic possibility that VOC B.1.1.7 is associated with an increased risk of death compared to non-VOC viruses.”
In addition, he speaks often to reporters about the deadliness of the new variant. Edmunds tells them, for example, that a “disaster” would ensue if lockdowns are eased too soon, because what first must be done is to “vaccinate much, much, much more widely than the elderly.”
FOLLOW THE FUNDS
Edmunds also happens to be the spouse of someone who, at least until April 2020, was an employee of GlaxoSmithKline (GSK) and held shares in the company. (Edmunds doesn’t disclose this in any of his media interviews that I’ve read and watched. He also doesn’t disclose his own stock holdings.)
According to an April 2020 Daily Telegraph article, Edmunds’s wife is Jeanne Pimenta and she works for GSK. The Daily Telegraph article states Edmunds asserted his partner had recently resigned from GSK. So it’s unclear whether Pimenta currently works there or not.
I did a little digging and found that the only Jeanne Pimenta LinkedIn profile indicates she’s currently director of epidemiology at GSK, while Jeanne Pimenta’s ResearchGate profile says she’s an epidemiologist at BioMarin Pharmaceutical. (I’ll have a bit more about Edmunds being married to a present or former Glaxo employee later in this article.)
In any case, GSK’s financial success is skyrocketing. On February 3 the company announced it’s collaborating with mRNA-vaccine company CureVac to spend 150 million Euros — approx $180 million — to make vaccines for the new variants. That effectively gives them first-entrant advantage in vaccines for the new variants. And that same Feb. 3 news release touts the new-variant vaccines as also able to serve as ‘booster’ shots after the initial rounds of vaccination.
In addition, GSK joined forces with CureVac to pump out, later this year, 100 million doses of CureVac’s ‘first-generation’ COVID-19 vaccine called ‘CvnCoV.’
Not only that: this fall GSK together with another international pharmaceutical firm, Sanofi, are scheduled to start producing what could turn out to be up to one billion doses of their COVID-19 vaccine annually. GSK’s understated Feb. 3 announcement of its Q4 2020 financial results said it will “continue to expect meaningful improvement in revenues and margins” because they are “building a high-value biopharma pipeline.”
Note that GSK and other pharma companies like Moderna and Pfizer are not responsible for damage and compensation payments to people seriously injured and killed by COVID-19 vaccines. Governments will pay instead – that is, if those injured and killed and their loved ones are able to beat the long odds and get any compensation at all.
And a remarkable February 8, 2021, investigative report in the German news outlet Welt Am Sonntag (which translates to World on Sunday) reveals another impetus for the wildly inaccurate modelling governments use to keep populations in a state of fear and control.
The German article shows that in March 2020 government officials enlisted [emphasis added]:
leading scientists from several research institutes and universities. Together, they were to produce a [mathematical-modelling] paper that would serve as legitimization for further tough political measures.”
These scientists obediently wrote a modelling paper tailored to the government’s instructions. The then-secret paper asserted that if lockdown measures were lifted immediately, up to one million Germans would die from COVID-19, some “agonizingly at home, gasping for breath,” after being turned away from overflowing hospitals.